StockpollyBeta
Get App
Popularity #2,092
CRBP · NASDAQ · Biotechnology

Corbus Pharmaceuticals (CRBP)

Develops CRB-701 for oncology and CRB-913 for obesity.

$7.74
After hours−0.01 (−0.19%)
At close$7.76(−1.52%)

  1. Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?

    Zacks Investment Research

  2. Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'

    Benzinga

  3. Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

    GlobeNewsWire

  4. Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer

    GlobeNewsWire

  5. Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript

    Seeking Alpha

  6. Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study

    MarketBeat

  7. Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript

    Seeking Alpha

  8. Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

    GlobeNewsWire

  9. Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

    GlobeNewsWire

  10. Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

    GlobeNewsWire

  11. Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

    GlobeNewsWire

  12. Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update

    GlobeNewsWire

  13. Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge

    Benzinga

  14. Assenagon Asset Management S.A. Has $1.53 Million Holdings in Corbus Pharmaceuticals Holdings, Inc. $CRBP

    Defense World

  15. How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%

    Zacks Investment Research

  16. Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

    GlobeNewsWire

  17. Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

    Seeking Alpha

  18. Assenagon Asset Management S.A. Takes Position in Corbus Pharmaceuticals Holdings, Inc. $CRBP

    Defense World

  19. Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript

    Seeking Alpha

  20. Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

    GlobeNewsWire

  21. Corbus Pharmaceuticals: Data Update And Fundraising Efforts Do Not Diminish The Thesis

    Seeking Alpha

  22. Corbus Pharmaceuticals Announces Pricing of Public Offering

    GlobeNewsWire

  23. Corbus Pharmaceuticals Announces Proposed Public Offering

    GlobeNewsWire

  24. Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel Transcript

    Seeking Alpha